DSIP — pharmacology
Molecular targets, mechanism of action, pharmacokinetics and interactions as characterised in humans.
§2Pharmacology
§2.1Molecular targets
Table 2. Molecular targets recorded for DSIP, with the character of the interaction and the potency where the Institute holds it.
| Target | Interaction | Note |
|---|---|---|
| Mechanism not established | No receptor identified | Despite five decades of study no receptor for DSIP has been identified, which is itself a substantive negative finding |
§2.2Mechanism of action
DSIP was isolated on the hypothesis that it mediated sleep induction. Subsequent work has not established a receptor, a consistent pharmacological effect, or a physiological role, and the somnogenic activity that gave the peptide its name has not been reproduced consistently. The Institute records that the compound is supplied principally on the strength of its name.[1,2]
§2.3Pharmacokinetics
- Terminal half-life
- reported as approximately 15 min
- Time to maximum concentration
- rapid
- Volume of distribution
- not published
- Plasma protein binding
- not published
- Clearance
- not published
- Bioavailability
- not established
Rapid peptidase degradation.
§2.4Interactions
- Not characterised
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research 2010;27(4):544–575. doi:10.1007/s11095-009-0045-6 · PMID 20143256
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.